Skin mucormycosis in dermatological practice: Dangerous coinfection during the COVID-19 pandemic (current state of the issue)

Abstract

The coronavirus SARS-COV-2 pandemic has caused an increase in the incidence of the population and significant losses that have claimed more than 6.8 million lives worldwide. In recent years, secondary microbial co-infections have caused serious concern: influenza, tuberculosis, typhoid fever, mucormycosis, etc. At the beginning of the catastrophic wave of coronavirus disease, there were reports of a rare but deadly mucormycosis, which quickly spread throughout the world. Currently, the relevance of this complication has increased significantly due to the pandemic of a new coronavirus infection, immunosuppression, diabetes mellitus and the massive use of glucocorticosteroids for the treatment of COVID-19.

It is proposed to revise diagnostic strategies to detect secondary co-infection. First-line therapy is amphotericin B in combination with surgery. Delaying antifungai therapy and surgical excision of diseased tissue increases mucormycosis-related mortality, requiring a high level of medical skill in both diagnostic and therapeutic aspects.

Keywords

mucormycosis / COVID-19 / diagnostics / treatment / amphotericin B / isavuconazole

References

[1] Nawaz S, Saleem M. COVID-19 and co-infections: A serious health threat requires combination diagnosis and therapy. Infect Disord Drug Targets. 2022. doi: 10.2174/1871526522666220407001744

[2] Nawaz S., Saleem M. COVID-19 and co-infections: A serious health threat requires combination diagnosis and therapy // Infect Disord Drug Targets. 2022. doi: 10.2174/1871526522666220407001744

[3] Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries. Mycoses. 2021;64(9):1028–1037. doi: 10.1111/myc.13335

[4] Rudramurthy S.M., Hoenigl M., Meis J.F., et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries // Mycoses. 2021. Vol. 64, N 9. Р. 1028–1037. doi: 10.1111/myc.13335

[5] Prakash S, Kumar A. Mucormycosis threats: A systemic review. J Basic Microbiol. 2022;63(2):119–127. doi: 10.1002/jobm.202200334

[6] Prakash S., Kumar A. Mucormycosis threats: A systemic review // J Basic Microbiol. 2022. Vol. 63, N 2. Р. 119–127. doi: 10.1002/jobm.202200334

[7] Sahu M, Shah M, Mallela VR, et al.; MuCOVIDYH Group. COVID-19 associated multisystemic mucormycosis from India: A multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome. Infection. 2022;51(2):407–416. doi: 10.1007/s15010-022-01891-y

[8] Sahu M., Shah M., Mallela V.R., et al.; MuCOVIDYH Group. COVID-19 associated multisystemic mucormycosis from India: A multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome // Infection. 2022. Vol. 51, N 2. Р. 407–416. doi: 10.1007/s15010-022-01891-y

[9] Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. doi: 10.1016/j.cmi.2018.07.011

[10] Jeong W., Keighley C., Wolfe R., et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports // Clin Microbiol Infect. 2019. Vol. 25, N 1. Р. 26–34. doi: 10.1016/j.cmi.2018.07.011

[11] Klimko N, Kozlova Y, Khostelidi S, et al. The burden of serious fungal diseases in Russia. Mycoses. 2015;58(S5):58–62. doi: 10.1111/myc.1238

[12] Klimko N., Kozlova Y., Khostelidi S., et al. The burden of serious fungal diseases in Russia // Mycoses. 2015. Vol. 58, N S5. Р. 58–62. doi: 10.1111/myc.1238

[13] Popova M, Rogacheva Y, Volkova A, et al. Invasive fungal diseases caused by rare pathogens in large cohort of pediatric and adult patients after hematopoietic stem cell transplantation and chemotherapy. Blood. 2019;134(Suppl 1):4497. doi: 10.1182/blood-2019-127961

[14] Popova M., Rogacheva Y., Volkova A., et al. Invasive fungal diseases caused by rare pathogens in large cohort of pediatric and adult patients after hematopoietic stem cell transplantation and chemotherapy // Blood. 2019. Vol. 134, Suppl. 1. Р. 4497. doi: 10.1182/blood-2019-127961

[15] Bonifaz A, Vázquez-González D, Tirado-Sánchez A, Ponce-Olivera RM. Cutaneous zygomycosis. Clin Dermatol. 2012;30(4):413–419. doi: 10.1016/j.clindermatol.2011.09.013

[16] Bonifaz A., Vázquez-González D., Tirado-Sánchez A., Ponce-Olivera R.M. Cutaneous zygomycosis // Clin Dermatol. 2012. Vol. 30, N 4. Р. 413–419. doi: 10.1016/j.clindermatol.2011.09.013

[17] John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi. 2021;7(4):298. doi: 10.3390/jof7040298

[18] John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis // J Fungi. 2021. Vol. 7, N 4. Р. 298. doi: 10.3390/jof7040298

[19] Benhadid-Brahmi Y, Hamane S, Soyer B, et al. COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review. J Mycol Med. 2022;32(1):101231. doi: 10.1016/j.mycmed.2021.101231

[20] Benhadid-Brahmi Y., Hamane S., Soyer B., et al. COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review // J Mycol Med. 2022. Vol. 32, N 1. Р. 101231. doi: 10.1016/j.mycmed.2021.101231

[21] Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26. doi: 10.3390/jof5010026

[22] Prakash H., Chakrabarti A. Global epidemiology of mucormycosis // J Fungi. 2019. Vol. 5, N 1. Р. 26. doi: 10.3390/jof5010026

[23] Colman S, Giusiano G, Colman C, et al. Hepatic failure and malnutrition as predisposing factors of cutaneous mucormycosis in a pediatric patient. Med Mycol Case Rep. 2021;(35):26–29. doi: 10.1016/j.mmcr.2021.12.005

[24] Colman S., Giusiano G., Colman C., et al. Hepatic failure and malnutrition as predisposing factors of cutaneous mucormycosis in a pediatric patient // Med Mycol Case Rep. 2021. N 35. Р. 26–29. doi: 10.1016/j.mmcr.2021.12.005

[25] Frolova EV, Filippova LV, Uchevatkina AE, et al. Features of the interaction of immune system cells with fungi of the order Mucorales (literature review). Problems Med Mycol. 2020;22(2):3–11. (In Russ).

[26] Фролова Е.В., Филиппова Л.В., Учеваткина А.Е., и др. Особенности взаимодействия клеток иммунной системы с грибами порядка Mucorales (обзор литературы) // Проблемы медицинской микологии, 2020, Т. 22, № 2. C. 3–11.

[27] Akhtar N, Wani AK, Tripathi KS, et al. The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review. Curr Res Biotechnol. 2022;(4):337–349. doi: 10.1016/j.crbiot.2022.08.001

[28] Akhtar N., Wani A.K., Tripathi K.S., et al. The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review // Curr Res Biotechnol. 2022. N 4. Р. 337–349. doi: 10.1016/j.crbiot.2022.08.001

[29] Ibrahim AS. Host cell invasion in mucormycosis: Role of iron. Curr Opin Microbiol. 2011;14(4):406–411. doi: 10.1016/j.mib.2011.07.004

[30] Ibrahim A.S. Host cell invasion in mucormycosis: Role of iron // Curr Opin Microbiol. 2011. Vol. 14, N 4. Р. 406–411. doi: 10.1016/j.mib.2011.07.004

[31] Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16–S22. doi: 10.1093/cid/cir865

[32] Ibrahim A.S., Spellberg B., Walsh T.J., Kontoyiannis D.P. Pathogenesis of mucormycosis // Clin Infect Dis. 2012. Vol. 54, Suppl. 1. Р. S16–S22. doi: 10.1093/cid/cir865

[33] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi: 10.1016/S0140-6736(20)30317-2

[34] Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury // Lancet. 2020. Vol. 395, N 10223. Р. 473–475. doi: 10.1016/S0140-6736(20)30317-2

[35] Attaluri P, Soteropulos C, Kim N, et al. Cutaneous mucormycosis of the upper extremity: Case reports highlighting rapid diagnosis and management. Ann Plast Surg. 2022;89(6):e18–e20. doi: 10.1097/SAP.0000000000003235

[36] Attaluri P., Soteropulos C., Kim N., et al. Cutaneous mucormycosis of the upper extremity: Case reports highlighting rapid diagnosis and management // Ann Plast Surg. 2022. Vol. 89, N 6. Р. e18–e20. doi: 10.1097/SAP.0000000000003235

[37] Devauschel P, Zhanna M, Frealle E. Mucormycosis in burn patients. J Fungi. 2019;5(1):25. doi: 10.3390/jof5010025

[38] Devauschel P., Zhanna M., Frealle E. Mucormycosis in burn patients // J Fungi. 2019. Vol. 5, N 1. Р. 25. doi: 10.3390/jof5010025

[39] Rrapi R, Chand S, Gaffney R, et al. Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: A case series. JAAD Case Rep. 2021;(17):92–95. doi: 10.1016/j.jdcr.2021.06.022

[40] Rrapi R., Chand S., Gaffney R., et al. Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: A case series // JAAD Case Rep. 2021. N 17. Р. 92–95. doi: 10.1016/j.jdcr.2021.06.022

[41] Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021;64(12):1452–1459. doi: 10.1111/myc.13338

[42] Pal R., Singh B., Bhadada S.K., et al. COVID-19-associated mucormycosis: An updated systematic review of literature // Mycoses. 2021. Vol. 64, N 12. Р. 1452–1459. doi: 10.1111/myc.13338

[43] Welch G, Sabour A, Patel K, et al. Invasive cutaneous mucormycosis: A case report on a deadly complication of a severe burn. IDCases. 2022;(30):E01613. doi: 10.1016/j.idcr.2022.e01613

[44] Welch G., Sabour A., Patel K., et al. Invasive cutaneous mucormycosis: A case report on a deadly complication of a severe burn // IDCases. 2022. N 30. Р. E01613. doi: 10.1016/j.idcr.2022.e01613

[45] Shastri M, Raval DM, Rathod VM. Cerebral mucormycosis in context with COVID-19 infection. J Association Physicians India. 2022;70(8):11–12.

[46] Shastri M., Raval D.M., Rathod V.M. Cerebral mucormycosis in context with COVID-19 infection // J Association Physicians India. 2022. Vol. 70, N 8. Р. 11–12.

[47] Krishna V, Bansal N, Morjaria J, Kaul S. COVID-19-associated pulmonary mucormycosis. J Fungi. 2022;8(7):711. doi: 10.3390/jof8070711

[48] Krishna V., Bansal N., Morjaria J., Kaul S. COVID-19-associated pulmonary mucormycosis // J Fungi. 2022. Vol. 8, N 7. Р. 711. doi: 10.3390/jof8070711

[49] Swain SK. Isolated involvement of palatine tonsil by COVID-19-associated Mucormycosis. Med J Dr DY Patil Vidyapeeth. 2022;15(7):S110–S113. doi: 10.4103/mjdrdypu.mjdrdypu_628_21

[50] Swain S.K. Isolated involvement of palatine tonsil by COVID-19-associated Mucormycosis // Med J Dr DY Patil Vidyapeeth. 2022. Vol. 15, N 7. Р. S110–S113. doi: 10.4103/mjdrdypu.mjdrdypu_628_21

[51] Amirzargar B, Jafari M, Ahmadinejad Z, et al. Subglottic mucormycosis in a COVID-19 patient: A rare case report. Oxford Medical Case Reports. 2022;(7):omac075. doi: 10.1093/omcr/omac075

[52] Amirzargar B., Jafari M., Ahmadinejad Z., et al. Subglottic mucormycosis in a COVID-19 patient: A rare case report // Oxford Medical Case Reports. 2022. N 7. Р. omac075. doi: 10.1093/omcr/omac075

[53] Luo S, Huang X, Li Y, Wang J. Isolated splenic mucormycosis secondary to diabetic ketoacidosis: A case report. BMC Infectious Diseases. 2022;22(1):596. doi: 10.1186/s12879-022-07564-3

[54] Luo S., Huang X., Li Y., Wang J. Isolated splenic mucormycosis secondary to diabetic ketoacidosis: A case report // BMC Infectious Diseases. 2022. Vol. 22, N 1. Р. 596. doi: 10.1186/s12879-022-07564-3

[55] Nepali R, Shrivastav S, Shah SD. Renal mucormycosis: Post-COVID-19 infection presenting as unilateral hydronephrosis in a young immunocompetent male. Case Reports in Nephrology. 2022;2022:3488031. doi: 10.1155/2022/3488031

[56] Nepali R., Shrivastav S., Shah S.D. Renal mucormycosis: Post-COVID-19 infection presenting as unilateral hydronephrosis in a young immunocompetent male // Case Reports Nephrology. 2022. Vol. 2022. Р. 3488031. doi: 10.1155/2022/3488031

[57] Muthe MM, Shirsath SD, Shirsath RD, Firke VP. A rare case of isolated vesical mucormycosis in a patient with COVID-19 pneumonitis. Indian J Radiol Imaging. 2022;32(3):408–410 doi: 10.1055/s-0042-1744137

[58] Muthe M.M., Shirsath S.D., Shirsath R.D., Firke V.P. A rare case of isolated vesical mucormycosis in a patient with COVID-19 pneumonitis // Indian J Radiol Imaging. 2022. Vol. 32, N 3. Р. 408–410. doi: 10.1055/s-0042-1744137

[59] Josefiak EJ, Foushee JH, Smith LC. Cutaneous mucormycosis. Am J Clin Pathol. 1958;30(6):547–552. doi: 10.1093/ajcp/30.6.547

[60] Josefiak E.J., Foushee J.H., Smith L.C. Cutaneous mucormycosis // Am J Clin Pathol. 1958. Vol. 30, N 6. Р. 547–552. doi: 10.1093/ajcp/30.6.547

[61] Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect. 2009;15(Suppl 5):41–45. doi: 10.1111/j.1469-0691.2009.02979.x

[62] Skiada A., Petrikkos G. Cutaneous zygomycosis // Clin Microbiol Infect. 2009. Vol. 15, Suppl. 5. Р. 41–45. doi: 10.1111/j.1469-0691.2009.02979.x

[63] Vinay K, Chandrasegaran A, Kanwar AJ, et al. Primary cutaneous mucormycosis presenting as a giant plaque: Uncommon presentation of a rare mycosis. Mycopathologia. 2014;178(1-2):97–101. doi: 10.1007/s11046-014-9752-6

[64] Vinay K., Chandrasegaran A., Kanwar A.J., et al. Primary cutaneous mucormycosis presenting as a giant plaque: Uncommon presentation of a rare mycosis // Mycopathologia. 2014. Vol. 178, N 1-2. Р. 97–101. doi: 10.1007/s11046-014-9752-6

[65] Castrejón-Pérez AD, Welsh EC, Miranda I, et al. Cutaneous mucormycosis. An Bras Dermatol. 2017;92(3):304–311. doi: 10.1590/abd1806-4841.20176614

[66] Castrejón-Pérez A.D., Welsh E.C., Miranda I., et al. Cutaneous mucormycosis // An Bras Dermatol. 2017. Vol. 92, N 3. Р. 304–311. doi: 10.1590/abd1806-4841.20176614

[67] Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML, et al. Mucormycosis with cutaneous involvement: A retrospective study of 115 cases at a tertiary care hospital in Mexico. Australas J Dermatol. 2021;62(2):162–167. doi: 10.1111/ajd.13508

[68] Bonifaz A., Tirado-Sánchez A., Hernández-Medel M.L., et al. Mucormycosis with cutaneous involvement: A retrospective study of 115 cases at a tertiary care hospital in Mexico // Australas J Dermatol. 2021. Vol. 62, N 2. Р. 162–167. doi: 10.1111/ajd.13508

[69] Mallis A, Mastronikolis SN, Naxakis SS, Papadas AT. Rhinocerebral mucormycosis: An update. Eur Rev Med Pharmacol Sci. 2010;14(11):987–992.

[70] Mallis A., Mastronikolis S.N., Naxakis S.S., Papadas A.T. Rhinocerebral mucormycosis: An update // Eur Rev Med Pharmacol Sci. 2010. Vol. 14, N 11. Р. 987–992.

[71] Simbli M, Hakim F, Koudieh M, Tleyjeh IM. Nosocomial post-traumatic cutaneous mucormycosis: A systematic review. Scand J Infect Dis. 2008;40(6-7):577–582. doi: 10.1080/00365540701840096

[72] Simbli M., Hakim F., Koudieh M., Tleyjeh I.M. Nosocomial post-traumatic cutaneous mucormycosis: A systematic review // Scand J Infect Dis. 2008. Vol. 40, N 6-7. Р. 577–582. doi: 10.1080/00365540701840096

[73] Shah H, Chisena E, Nguyen B, et al. Successful management of mucormycosis infection secondary to motor vehicle accident in a healthy adolescent: A case report. Med Mycol Case Rep. 2022;(38):36–40. doi: 10.1016/j.mmcr.2022.10.004

[74] Shah H., Chisena E., Nguyen B., et al. Successful management of mucormycosis infection secondary to motor vehicle accident in a healthy adolescent: A case report // Med Mycol Case Rep. 2022. N 38. Р. 36–40. doi: 10.1016/j.mmcr.2022.10.004

[75] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821. doi: 10.1086/588660

[76] De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group // Clin Infect Dis. 2008. Vol. 46, N 12. Р. 1813–1821. doi: 10.1086/588660

[77] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–1376. doi: 10.1093/cid/ciz1008

[78] Donnelly J.P., Chen S.C., Kauffman C.A., et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium // Clin Infect Dis. 2020. Vol. 71, N 6. Р. 1367–1376. doi: 10.1093/cid/ciz1008

[79] Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–е421. doi: 10.1016/S1473-3099(19)30312-3

[80] Cornely O.A., Alastruey-Izquierdo A., Arenz D., et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium // Lancet Infect Dis. 2019. Vol. 19, N 12. Р. e405–е421. doi: 10.1016/S1473-3099(19)30312-3

[81] Taraskina A, Vasilyeva NV, Pchelin IM, et al. Molecular genetic methods for the determination and species identification of fungi of the order Mucorales in accordance with global recommendations for the diagnosis and therapy of mucoromycosis (literature review). Problems Med Mycol. 2020;22(1):3–14. (In Russ). doi: 10.24412/1999-6780-2020-1-3-14

[82] Тараскина А.Е., Васильева Н.В., Пчелин И.М., и др. Молекулярно-генетические методы определения и видовой идентификации грибов порядка Mucorales в соответствии с глобальными рекомендациями по диагностике и терапии мукоромикоза (обзор литературы) // Проблемы медицинской микологии. 2020. Т. 22, № 1. С. 3–14. doi: 10.24412/1999-6780-2020-1-3-14

[83] Cornely OA, Köhler P, Mellinghoff SC, Klimko N. Mucormycosis 2018: The European Confederation for Medical Mycology (ECMM) method for assessing the quality of mucormycosis treatment. doi: 10.4126/FRL01-006409504

[84] Cornely O.A., Köhler P., Mellinghoff S.C., Klimko N. Mucormycosis 2018: The European Confederation for Medical Mycology (ECMM) method for assessing the quality of mucormycosis treatment. doi: 10.4126/FRL01-006409504

[85] Popova MO, Rogacheva YA. Mucormycosis: Modern possibilities of diagnosis and treatment, existing problems and new trends in therapy. Clin Microbiol Antimicrobial Chemother. 2021;23(3):226–238. (In Russ).

[86] Попова М.О., Рогачева Ю.А. Мукормикоз: современные возможности диагностики и лечения, существующие проблемы и новые тенденции в терапии // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 3. С. 226–238.

[87] Beeraka NM, Liu J, Sukocheva O, et al. Antibody responses and CNS pathophysiology of mucormycosis in chronic SARS-CoV-2 infection: Current therapies against mucormycosis. Current Medicinal Chemistry. 2022;29(32):5348–5357. doi: 10.2174/0929867329666220430125326

[88] Beeraka N.M., Liu J., Sukocheva O., et al. Antibody responses and CNS pathophysiology of mucormycosis in chronic SARS-CoV-2 infection: Current therapies against mucormycosis // Current Medicinal Chemistry. 2022. Vol. 29, N 32. Р. 5348–5357. doi: 10.2174/0929867329666220430125326

[89] Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(Suppl 1):93–101. doi: 10.1093/mmy/myx101

[90] Skiada A., Lass-Floerl C., Klimko N., et al. Challenges in the diagnosis and treatment of mucormycosis // Med Mycol. 2018. Vol. 56, Suppl. 1. Р. 93–101. doi: 10.1093/mmy/myx101

[91] Shetty SS, Shetty S, Venkatesh SB. Integrated treatment strategies and prosthetic rehabilitation for COVID-19-associated mucormycosis. J Datta Meghe Institute Medical Sci University. 2022;17(5):S120–123.

[92] Shetty S.S., Shetty S., Venkatesh S.B. Integrated treatment strategies and prosthetic rehabilitation for COVID-19-associated mucormycosis // J Datta Meghe Institute Medical Sci University. 2022. Vol. 17, N 5. Р. S120–123.

[93] Abdelmonem R, Backx M, Vale L, et al. Successful treatment of Mucor circinelloides in a Burn patient. Burns Open. 2022;6(2):77–81.

[94] Abdelmonem R., Backx M., Vale L., et al. Successful treatment of Mucor circinelloides in a Burn patient // Burns Open. 2022. Vol. 6, N 2. Р. 77–81.

[95] Burova SA, Taganov AV, Kashtanova AA, Gobacheva YV. Mucormycosis is a dangerous and real fungal superinfection during the COVID-19 pandemic. In: Successes of medical mycology: Collection of materials of the All-Russian Congress on Medical Microbiology, Clinical Mycology and Immunology. Vol. XXIII. Chapter 2: Focal and invasive mycoses. 2022. Р. 51–54. (In Russ).

[96] Бурова С.А., Таганов А.В., Каштанова А.А., Гобачёва Ю.В. Мукормикоз ― опасная и реальная грибковая суперинфекция в период пандемии COVID-19 // Успехи медицинской микологии: сборник материалов Всероссийского конгресса по медицинской микробиологии, клинической микологии и иммунологии. Т. XXIII. Гл. 2: Фокальные и инвазивные микозы. 2022. С. 51–54.

[97] Marty FM, Ostrosky-Zeichner L, Cornely OA, et al.; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837. doi: 10.1016/S1473-3099(16)00071-2

[98] Marty F.M., Ostrosky-Zeichner L., Cornely O.A., et al.; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis // Lancet Infect Dis. 2016. Vol. 16, N 7. Р. 828–837. doi: 10.1016/S1473-3099(16)00071-2

RIGHTS & PERMISSIONS

Eco-Vector